3 results
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Approved WMOCompleted
Primary Objectives:- To assess chemoprophylactic activity of single oral doses of M5717 administered after DVI of Plasmodium falciparum sporozoites (PfSPZ) challenge in healthy participants. - To explore the dose-exposure-response relationship of a…
Approved WMOCompleted
Part 1: To evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks.Part 2: evaluate long-term safety profile of BIIB033 as an add-on therapy in subjects with MS.